宫颈癌组织中PD-L1的表达及临床意义分析

目的:探讨宫颈癌组织中程序性死亡因子配体(Programmed death ligand 1,PD-L1)的表达及临床意义,为宫颈癌免疫治疗提供理论和实验基础。方法:采用免疫组织化学染色的方法检测10例正常宫颈组织、71例宫颈上皮内瘤变(Cervical intraepithelial neoplasias,CIN)组织和89例宫颈癌组织中PD-L1蛋白的表达,分析PD-L1的表达与宫颈癌患者临床病理参数(临床分期、病理类型、年龄、淋巴转移)的相关性。结果:正常宫颈组织中无PD-L1表达,CIN中PD-L1表达的免疫评分低,呈弱阳性;宫颈癌中PD-L1表达的免疫评分高,呈强阳性。CIN和宫颈癌组织中PD-L1的阳性表达率分别为42%(30/41)和75%(66/89),其差异有统计学意义(P0.05)。PD-L1的表达与宫颈癌患者年龄、病理分级、淋巴转移无关(P0.05),而与患者临床分期显著相关(P=0.0021)。结论:PD-L1的表达上调可能参与了宫颈癌的发生和发展。

Expression and Clinical Significance of PD-L1 in the Cervical Cancer

ABSTRACT Objective: To investigate the expression and clinical significance of PD-L1 in the cervical cancer, thus provide theoretical and experimental basis for the immunotherapy of cervical cancer. Methods: The protein expression of PD-L1 was determined in 10 cases of normal cervical tissue, 71 cases of CIN and 89 cases of cervical cancer by immunohistochemical staining, then the relationship between PD-L1 expression level and clinical pathological parameters(FIGO stage, histology type, age, lymph node) were analyzed. Results: There was no PD-L1 expression in the normal cervical tissues. The immunological score of PD-L1 expression in CIN was low and weakly positive. The immunological score of PD-L1 expression in cervical cancer was high and strongly positive. The positive expression rates of PD-L1 in CIN and cervical cancer tissues were 42% (30/41) and 75% (66/89), respectively(P<0.05). The expression of PD-L1 was not correlated with age, pathological grade and lymphatic metastasis(P>0.05), but was closely related to the clinical stage(P=0.0021). Conclusion: The up-regulation of PD-L1 expression may be involved in the development and progression of cervical cancer.